| pubmed-article:7903915 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0057223 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0020365 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0003289 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0011082 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0025381 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0017431 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C1332830 | lld:lifeskim |
| pubmed-article:7903915 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:7903915 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7903915 | pubmed:dateCreated | 1994-2-4 | lld:pubmed |
| pubmed-article:7903915 | pubmed:abstractText | Debrisoquin and S-mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patients treated with neuroleptic or antidepressant agents. One patient (1.4%) was classified as a poor metabolizer of S-mephenytoin. Between both neuroleptic- and antidepressant-treated patients, the distribution of the debrisoquin metabolic ratio was shifted toward higher values compared with 54 drug-free healthy subjects. Forty percent of patients treated with neuroleptics and 5% of patients treated with antidepressants were classified as poor metabolizers of debrisoquin. CYP2D6 genotype analysis in 36 neuroleptic-treated patients confirmed that the high metabolic ratios were attributable to inhibition of CYP2D6 and not to overrepresentation of subjects with poor metabolizer genotypes. In 48 selected Spanish drug-free subjects, CYP2D6 genotype predicted the phenotype with 95% accuracy. Neuroleptics and antidepressants interfere at therapeutic doses with phenotyping for CYP2D6 but not for S-mephenytoin hydroxylation capacity. In psychotropic-treated patients, genotyping provides a valuable tool for prediction of the CYP2D6 phenotype. | lld:pubmed |
| pubmed-article:7903915 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7903915 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7903915 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7903915 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:7903915 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:7903915 | pubmed:author | pubmed-author:JohanssonII | lld:pubmed |
| pubmed-article:7903915 | pubmed:author | pubmed-author:DahlM LML | lld:pubmed |
| pubmed-article:7903915 | pubmed:author | pubmed-author:CobaledaJJ | lld:pubmed |
| pubmed-article:7903915 | pubmed:author | pubmed-author:HerreraA MAM | lld:pubmed |
| pubmed-article:7903915 | pubmed:author | pubmed-author:LLerenaAA | lld:pubmed |
| pubmed-article:7903915 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7903915 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:7903915 | pubmed:geneSymbol | CYP2D6 | lld:pubmed |
| pubmed-article:7903915 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7903915 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7903915 | pubmed:pagination | 606-11 | lld:pubmed |
| pubmed-article:7903915 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:meshHeading | pubmed-meshheading:7903915-... | lld:pubmed |
| pubmed-article:7903915 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7903915 | pubmed:articleTitle | Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. | lld:pubmed |
| pubmed-article:7903915 | pubmed:affiliation | Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden. | lld:pubmed |
| pubmed-article:7903915 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7903915 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7903915 | lld:pubmed |
